jp-morgan-healthcare-conference-logo

Now in its 37th year, the conference has ballooned from a small event with 150 attendees that was essentially the " birth of biotech," to an event attended by everyone from the biggest pharma company to the smallest biotech. JPMorgan said more than 485 companies are scheduled to present this year.

Bahija-Jallal-MedImmune-image

Congratulations to Bahija on making MedImmune the leading BioHealth company in Maryland and accelerating its growth. Also many thanks for the MedImmune longtime support of BHI and helping the BioHealth Capital Region become the 4th largest Life Science region in the country.

Six years after AstraZeneca’s then new CEO Pascal Soriot named Bahija Jallal president of the big MedImmune subsidiary in Gaithersburg, MD, putting her at the center of the company’s R&D turnaround plans, the longtime pharma exec is joining the great migration of industry professionals to biotech.

emergent-abdun-nabi-kramer-2-image.png

Many thanks to Dan for his leadership of Emergent, his service as a loyal BHI Board Member and for helping accelerate the growth of the BIO Health Capital Region

Emergent BioSolutions Inc. (EBS) today announced that its CEO Daniel J. Abdun-Nabi will be retiring and that its board of directors has unanimously appointed Robert G. Kramer, Sr., the company’s current president and COO, to succeed him as president and CEO, effective April 1, 2019. Mr. Abdun-Nabi has also indicated that he plans to step down as a member of the Emergent board of directors, and Emergent expects the board of directors to appoint Mr. Kramer to fill the board vacancy created by Mr. Abdun-Nabi’s retirement.

ssti-logo

Here is a significant opportunity for MARYLAND to grow in SBIR success.

One of the best ways to measure the effectiveness of state programs intended to encourage the success of SBIR applications is the approval-rate of their submissions. Although this data has been historically unavailable across every federal agency, it is now accessible for the National Institutes of Health (NIH), the second largest provider of SBIR/STTR awards, according to a 2018 Digest report. The NIH distributed $446.2 million in SBIR/STTR awards in 2017, with every state except North and South Dakota receiving an award. Although California and Massachusetts had the most successful SBIR/STTR applications in 2017, accounting for roughly one-third of the total when combined, neither state ranked among the top 10 in success rate.

Atlas-Venture-logo

A biotechnology venture capital firm is ringing in the new year with its latest fund, having raised a quarter of $1 billion.

Cambridge, Massachusetts-based Atlas Venture said Wednesday that it closed its first Opportunity Fund, or AVOF I, with an oversubscribed fund raise of $250 million. The firm plans to invest the money in companies already in its portfolio.

maryland-life-sciences-header-logo

Tuesday, January 15, 2019 8:30AM - 10:30AM

GSK 9911 Belward Campus Drive Rockville, MD 20850

The Maryland Life Sciences, a division of the Maryland Tech Council, brings together vaccine leaders to discuss current breakthroughs in the world of vaccines and immunotherapeutics. This breakfast meeting will address innovating strategies to meet current health threats, changing technology for vaccine manufacturing and provide a snapshot of where vaccine development stands today.

Join us for breakfast, networking and a discussion to hear about the experiences and insights on the current state and projected future of treatments. Local leaders will also discuss challenges and opportunities that come with vaccine and immunotherapy development used by companies in our State.

us-state-map-pixa

Different places have different levels of educational achievement.

The American Community Survey is an annual survey run by the Census Bureau to allow the government, corporate and academic researchers, and anyone who is curious about demographics to better understand the US population. Among many other subjects, the ACS includes questions about respondents' education levels.